A Phase 2 interventional study of BIBF1120 and Placebo in Ovarian Neoplasms, sponsored by Boehringer Ingelheim. Completed at 11 sites in United Kingdom. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-15.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies in Ovarian Neoplasms with a site in United Kingdom — 54 open to participants now, 85 under way, 25 of them phase 3. Ovarian Neoplasms · United Kingdom.
Among the 293 studies in Ovarian Neoplasms with a site in United Kingdom, this one is the 165th largest by enrollment of the 249 interventional ones that give a count, is one of 11 that started in 2006, is one of 73 in phase 2, and was the 58th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →54 of the 293 studies in Ovarian Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:
Epitopea Ltd · Sites in United Kingdom
Ages 18+ · Women only
Merck Sharp & Dohme LLC · Sites in United Kingdom, United States, Israel and 2 more countries
Ages 18+ · Women only
National and Kapodistrian University of Athens · Sites in United Kingdom, Czechia, Greece and 2 more countries
Ages 35+ · Women only · Healthy volunteers
GlaxoSmithKline · Sites in United Kingdom, Australia, Canada and 2 more countries
Ages 18+ · Women only
Zelluna Immunotherapy AS · Sites in United Kingdom
Ages 18–75
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 122 · Phase 3 76 · Phase 4 1
First in 1989; this study’s year is marked. 11 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 89 is above the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 158 across the 249 interventional studies, 235 across the 35 observational. Of the 177 that completed or were terminated, 64 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
182 of 293 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 6 studies filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
25 of the studies in Ovarian Neoplasms with a site in United Kingdom that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05059522Phase 3PfizerContinued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | 2026-12-31 |
| NCT05445778Phase 3AbbVieMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT07214779Phase 3Incyte CorporationStudy to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | 2027-10-12 |
Add all 25 to your calendar (.ics) → With an account.
Among the 293 studies in Ovarian Neoplasms with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to estimate the Progression Free Survival Rates (PFS) of patients with relapsed ovarian cancer after 9 months of continuous treatment with either BIBF 1120 or matching placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BIBF1120
Drug: Placebo
PFS Rate at 36 Weeks (After 9 Months)
The rate (probability) of being progression free at Week 36. Progression Free Survival (PFS) was defined according to RECIST version 1.0 from the time of first study drug administration to the first time of either objective tumour progression, the appearance of ≥1 new tumour lesion(s), occurrence or significant progression of malignant ascites, tumour related death, or the time when patients were censored at last known follow up. The rate is the Kaplan-Meier estimated percent probability.
Time frame: 36 weeks (after 9 months)
PFS Rate at 12 Weeks (After 3 Months) and 24 Weeks ( After 6 Months)
The rate (probability) of being progression free at Week 12 and Week 24. Progression Free Survival (PFS) was defined according to RECIST version 1.0 from the time of first study drug administration to the first time of either objective tumour progression, the appearance of ≥1 new tumour lesion(s), occurrence or significant progression of malignant ascites, tumour related death, or the time when patients were censored at last known follow up. The rate is the Kaplan-Meier estimated percent probability.
Time frame: 12 weeks (after 3 months) and 24 weeks ( after 6 months)
Time to Tumour Progression
Time to Tumour Progression according to RECIST version 1.0 , CA-125 (ovarian tumour marker) levels and RECIST + CA-125 levels. For CA-125, progressive disease was defined on the basis of progressive serial elevations of CA-125 according to the following criteria: Patients with elevated CA-125 pre-treatment and normalisation of CA-125 had to show evidence of CA-125 levels ≥2 x ULN on 2 occasions at least 1 week apart. or Patients with elevated CA-125 pre-treatment that never normalised had to show evidence of CA-125 levels ≥2 x the nadir value on 2 occasions at least 1 week apart. or Patients with CA-125 in the normal range pre-treatment had to show evidence of CA-125 levels ≥2 x ULN on 2 occasions at least 1 week apart. Composite (RECIST+CA-125) endpoint is the RECIST progressive disease (PD) if it occurred or the CA-125 PD if it occurred in the absence of RECIST PD.
Time frame: 9 months
Time to Death
This end point was not determined as no patients died during the trial.
Time frame: 9 months
Incidence and Intensity of Adverse Events With Grading According CTCAE
Incidence and intensity of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0).
Time frame: First drug administration until 28 days after last drug administration,up until 309 days
Clinical Relevant Abnormalities for Laboratory Parameters
Clinical Relevant Abnormalities for laboratory parameters. Any new or clinically relevant worsening of baseline conditions was reported as Adverse Events.
Time frame: First drug administration until 28 days after last drug administration, up until 309 days
| Milestone | Nintedanib | Placebo |
|---|---|---|
| Started | 44 | 40 |
| Completed | 5 | 0 |
| Not completed | 39 | 40 |
| Withdrew: Progressive disease | 27 | 30 |
| Withdrew: Adverse event other disease worsening | 2 | 1 |
| Withdrew: Other adverse event | 7 | 7 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Reason other than listed above | 2 | 2 |
The rate (probability) of being progression free at Week 36. Progression Free Survival (PFS) was defined according to RECIST version 1.0 from the time of first study drug administration to the first time of either objective tumour progression, the appearance of ≥1 new tumour lesion(s), occurrence or significant progression of malignant ascites, tumour related death, or the time when patients were censored at last known follow up. The rate is the Kaplan-Meier estimated percent probability.
| percent probability of PFS | Nintedanib | Placebo |
|---|---|---|
| PFS Rate at 36 Weeks (After 9 Months) | 15.6 (3.8 to 27.3) | 2.9 (0.0 to 8.4) |
The rate (probability) of being progression free at Week 12 and Week 24. Progression Free Survival (PFS) was defined according to RECIST version 1.0 from the time of first study drug administration to the first time of either objective tumour progression, the appearance of ≥1 new tumour lesion(s), occurrence or significant progression of malignant ascites, tumour related death, or the time when patients were censored at last known follow up. The rate is the Kaplan-Meier estimated percent probability.
| percent probability of PFS | Nintedanib | Placebo |
|---|---|---|
| at 24 weeks ( after 6 months) | 26.7 (12.5 to 40.8) | 17.3 (5.2 to 29.4) |
| at 12 weeks (after 3 months) | 45.3 (29.5 to 61.2) | 46.2 (30.5 to 61.8) |
Time to Tumour Progression according to RECIST version 1.0 , CA-125 (ovarian tumour marker) levels and RECIST + CA-125 levels. For CA-125, progressive disease was defined on the basis of progressive serial elevations of CA-125 according to the following criteria: Patients with elevated CA-125 pre-treatment and normalisation of CA-125 had to show evidence of CA-125 levels ≥2 x ULN on 2 occasions at least 1 week apart. or Patients with elevated CA-125 pre-treatment that never normalised had to show evidence of CA-125 levels ≥2 x the nadir value on 2 occasions at least 1 week apart. or Patients with CA-125 in the normal range pre-treatment had to show evidence of CA-125 levels ≥2 x ULN on 2 occasions at least 1 week apart. Composite (RECIST+CA-125) endpoint is the RECIST progressive disease (PD) if it occurred or the CA-125 PD if it occurred in the absence of RECIST PD.
| days | Nintedanib | Placebo |
|---|---|---|
| according to RECIST and CA-125 | 83.00 (78.0 to 149.0) | 84.00 (78.0 to 87.0) |
| according to CA-125 | 85.00 (79.0 to 149.0) | 86.00 (67.0 to 113.0) |
| according to RECIST | 143.0 (82.0 to 175.0) | 85.0 (78.0 to 89.0) |
This end point was not determined as no patients died during the trial.
No measurements were reported for this outcome.
Incidence and intensity of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0).
| percentage of participants | Nintedanib | Placebo |
|---|---|---|
| CTCAE grade 1 | 2.3 | 25.0 |
| CTCAE grade 2 | 34.9 | 42.5 |
| CTCAE grade 3 | 53.5 | 25.0 |
| CTCAE grade 4 | 7.0 | 2.5 |
| CTCAE grade 5 | 0.0 | 0.0 |
Clinical Relevant Abnormalities for laboratory parameters. Any new or clinically relevant worsening of baseline conditions was reported as Adverse Events.
| Percentage of participants | Nintedanib | Placebo |
|---|---|---|
| Alanine aminotransferase increased | 37.2 | 7.5 |
| Gamma-glutamyltransferase increased | 30.2 | 2.5 |
| Aspartate aminotransferase increased | 25.6 | 2.5 |
| Blood alkaline phosphatase increased | 7.0 | 5.0 |
| Blood lactate dehydrogenase increased | 4.7 | 0.0 |
| Blood alkaline phosphatase | 0.0 | 2.5 |
| Blood alkaline phosphatase abnormal | 2.3 | 2.5 |
| Lymphocyte count decreased | 0.0 | 2.5 |
| Vitamin B12 decreased | 0.0 | 2.5 |
| Alanine aminotransferase abnormal | 2.3 | 0.0 |
| Blood lactate dehydrogenase abnormal | 2.3 | 0.0 |
| Gamma-glutamyltransferase abnormal | 2.3 | 0.0 |
| Neutrophil count decreased | 2.3 | 0.0 |
| White blood cells urine positive | 2.3 | 0.0 |
| Blood pressure increased | 0.0 | 2.5 |
| Electrocardiogram T wave amplitude decreased | 0.0 | 2.5 |
| Liver function test abnormal | 2.3 | 0.0 |
Collected over First drug administration until 28 days after last drug administration, up until 309 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nintedanib | — | 14/43 (32.6%) | 42/43 (97.7%) |
| Placebo | — | 10/40 (25%) | 37/40 (92.5%) |
| Event | Nintedanib | Placebo |
|---|---|---|
| VomitingGastrointestinal disorders | 10/43 | 0/40 |
| AscitesGastrointestinal disorders | 6/43 | 5/40 |
| Abdominal painGastrointestinal disorders | 4/43 | 2/40 |
| DiarrhoeaGastrointestinal disorders | 3/43 | 0/40 |
| Intestinal obstructionGastrointestinal disorders | 2/43 | 1/40 |
| PancytopeniaBlood and lymphatic system disorders | 0/43 | 1/40 |
| Small intestinal obstructionGastrointestinal disorders | 1/43 | 1/40 |
| Catheter related infectionInfections and infestations | 0/43 | 1/40 |
| DehydrationMetabolism and nutrition disorders | 0/43 | 1/40 |
| Lung neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/43 | 1/40 |
| Event | Nintedanib | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 33/43 | 14/40 |
| NauseaGastrointestinal disorders | 32/43 | 13/40 |
| Abdominal painGastrointestinal disorders | 23/43 | 15/40 |
| VomitingGastrointestinal disorders | 23/43 | 9/40 |
| Alanine aminotransferase increasedInvestigations | 16/43 | 3/40 |
| FatigueGeneral disorders | 12/43 | 11/40 |
| Gamma-glutamyltransferase increasedInvestigations | 12/43 | 1/40 |
| ConstipationGastrointestinal disorders | 9/43 | 11/40 |
| AnorexiaMetabolism and nutrition disorders | 11/43 | 6/40 |
| Aspartate aminotransferase increasedInvestigations | 10/43 | 1/40 |
Treated set consist of all patients who received at least 1 dose of nintedanib or placebo. Note: 43 patients were included in the analyses instead of 44 patients in nintedanib arm as one patient was excluded after drug administration due to important protocol violation.
| Age, Continuous(years) | Nintedanib | Placebo | Total |
|---|---|---|---|
| Mean | 58.4 ± 9.5 | 61.3 ± 9.1 | 59.8 ± 9.3 |
| Sex: Female, Male(Participants) | Nintedanib | Placebo | Total |
|---|---|---|---|
| Female | 43 | 40 | 83 |
| Male | 0 | 0 | 0 |
The record gives a start of Mar 2006, a primary completion of Sep 2008 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2014, 6 years 3 months after primary completion. A results delay was requested in May 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib